Detection of gene marker for hormone-resistance of prostatic carcinoma

本实验室建立了雄激素非依赖性前列腺癌细胞系(LNCaP-N)的DNA芯片，与雄激素依赖亲本细胞系(LNCaP)相比，LNCaP-N强表达胰岛素样生长因子结合蛋白2(IGFBP-2)。为此，我们采用实时荧光定量RT-PCR方法检测了IGFBP-2在前列腺疾病中的表达。在21例接受激素治疗的前列腺癌患者中，档案标本取自经尿道电切术。前列腺癌组织中IGFBP-2的表达水平显著高于未经治疗的前列腺癌组织(P&lt；0.0001)。在前列腺癌中，低级别和高级别的IGFBP-2表达水平差异无统计学意义。局部病例和晚期病例的IGFBP-2表达水平差异无统计学意义。此外，IGFBP-2的表达水平与特定原因的生存率和复发率无关。另一方面，我们比较了4例转移性前列腺癌患者回肠骨髓和原发灶组织中IGFBP-2的表达水平，发现骨髓中IGFBP-2的表达水平低于原发灶。在21例接受激素治疗的癌症患者中，IGFBP-2的表达水平高于未治疗的癌症患者。此外，我们还研究了前列腺癌胸苷合成酶和二氢嘧啶脱氢酶的基因表达水平，但没有认识到临床病理因素之间的相关性。

As a result of DNA microarrays for androgen-independent prostatic carcinoma cell line (LNCaP-N) established in our laboratory, LNCap-N strongly expressed insulin like growth factor-binding protein 2 (IGFBP-2) compared with androgen-dependent parent cell line (LNCaP). Therefore we investigated the expressions of IGFBP-2 in human prostate diseases by real time quantitative RT-PCR method.Archival samples were obtained from prostate needle biopsy specimens in 39 BPH cases and 69 nontreatment-prostatic carcinoma cases. In 21 prostate carcinoma cases treated hormone therapy, archival samples were obtained from transurethral resection. The IGFBP-2 expression levels in BPH cases was statistically higher than those in no-treated prostate carcinoma cases (P<0.0001). In prostate carcinomas, there was no difference between the IGFBP-2 expression levels of low-grade cases and those of high-grade cases. And, we did not show significant difference between the IGFBP-2 expression levels of localized cases and those of advanced cases. Moreover, the IGFBP-2 expression levels did not associated to the cause-specific survival rate and recurrence rate. On the other hand, we compared the IGFBP-2 expression levels with ileum bone marrow and with primary tumor lesion in 4 metastatic prostatic carcinoma cases, and that of bone marrow tended to be low than that of primary tumor. In 21 cases performed hormone therapy, the IGFBP-2 expression levels were higher than those of no-treated carcinoma cases. These results showed statistically significant difference (P=0.0158).Furthermore, we studyed mRNA expression level of thymidylate synthase and dihydropynmidine dehydrogenase for prostatic carcinoma, but did not recognize the correlation between clinicopathologic factor.